Carbidopa And Levodopa Capsule, Extended Release
Pricing Report NDC 70710-2140-1
Current Package Pricing Information
The current wholesale acquisition cost for Carbidopa And Levodopa (NDC 70710-2140-1) is $3.24145 per EA. This benchmark price is based on the National Average Drug Acquisition Cost (NADAC) and has been effective since Jun 17, 2026.
As a a human prescription drug provided by Zydus Pharmaceuticals Usa Inc., this medication is distributed in a 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE configuration. The pricing data is derived from C/I - Chain or Independent Pharmacy surveys, reflecting the actual invoice prices paid by community pharmacies to drug wholesalers.
NADAC Pricing Summary
NADAC pricing snapshot for this package NDC
Acquisition Cost $3.24145 Per EA
The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation.
Historical Pricing Trends & Acquisition Cost Benchmarks
The current wholesale price for (NDC ) is based on the most recent federal survey data. As this is a newer entry or has a stable pricing model, the chart below reflects the current established benchmark of $3.24145 per EA.
| Date | Unit Price | Unit | Source | Method | Rate |
|---|---|---|---|---|---|
| Jun 17, 2026 | $3.24145 | EA | C/I - Chain or Independent Pharmacy | Code 1, 6 | G - Generic |
Pricing Methodology Legend
- Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey.
- Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation.
Understanding NADAC Pricing Data
The National Average Drug Acquisition Cost (NADAC) is compiled by the Centers for Medicare and Medicaid Services (CMS). This data is derived from random monthly surveys of more than 60,000 pharmacies across all 50 states.
Important Price Distinction:
The prices listed on this page represent the wholesale invoice price paid by pharmacies to acquire the drug. This is NOT the retail price paid by consumers at the pharmacy counter. Final patient costs typically include pharmacy markups, professional dispensing fees, and insurance adjustments.
NADAC Pricing Data Last Updated on: June 17, 2026
